Catalyst
Slingshot members are tracking this event:
Opko (OPK) to begin phase 2b trial on TT401—an oxytomodulin dual GLP1/Glucagon agonist for diabetes and obesity—in early 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| OPK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 23, 2018
Occurred Source:
http://investor.opko.com/news-releases/news-release-details/opko-health-enrolls-first-patient-phase-2b-study-opk88003-treat
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tt401, Diabetes, Obesity, Glp-1/glucagon Dual Agonist
